Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
SlideShare a Scribd company logo

Antileprotic drugs - drdhriti

•Download as PPTX, PDF•
•
http://neigrihms.gov.in/
http://neigrihms.gov.in/

This document summarizes information about leprosy (Hansen's disease), including: 1. It is caused by Mycobacterium leprae bacteria and primarily affects the skin, nerves, and mucous membranes. 2. There are different classifications of leprosy based on immune response and symptoms, including paucibacillary (few bacteria) and multibacillary (many bacteria) forms. 3. Leprosy is now curable using multidrug therapy regimens of 6 months to 1 year depending on classification, helping to reduce cases from 12 million to 2.7 million.

Related slideshows

Antiamoebic drugs
Antiamoebic drugsAntiamoebic drugs
Antiamoebic drugs
 
Antiparkinsonian drugs
Antiparkinsonian drugsAntiparkinsonian drugs
Antiparkinsonian drugs
 
Class antileprotic drugs
Class antileprotic drugsClass antileprotic drugs
Class antileprotic drugs
 
1 of 17
Dr. D. K. Brahma Associate Professor Department of Pharmacology NEIGRIHMS, Shillong
 Leprosy is caused by a slow-growing type of bacteria called Mycobacterium leprae (M. leprae)  Also known as Hansen's disease, after the scientist who discovered M. leprae in 1873 - Dr. Gerhard Henrik Armauer Hansen of Norway  Bears social stigma  It primarily affects the skin, mucous membrane and the peripheral nerves  Long Incubation period (3 – 5 years)  Curable now – deformities/defects – may not reverse
 Chaulmoogra oil  Discovery of sulfonamides  1940 onwards 1. Sulfones – Dapsone ( DDS) 2. Phenazine derivative - Clofazimine 3. Antitubercular drugs - Rifampicin, Ethionamide 4. Other Antibiotics: Ofloxacin, Moxifloxacin, Minocycline and Clarithromycin
 The simplest, oldest, cheapest, most active and most commonly used  Diamino diphenyl sulfone (DDS)  MOA:  Leprostatic even at low concentration – higher conc. Arrests growth of may other bacteria  Chemically related to Sulfonamides – same mechanism – inhibition of incorporation of PABA into folic acid (folic acid synthase)  Specificity to M leprae – affinity for folate synthase  Doses for acute infection – too toxic  Activity:  Used alone – resistance – MDT needed  Resistance – Primary and Secondary (mutation of folate synthase – lower affinity)  2.5% to 40% Vs 20% Resistance  However, 100 mg/day – high MIC -500 times and continued to be effective to low and moderately resistant Bacilli (low % of resistant patient)  Persisters. Also has antiprotozoal action (Falciparum and T. gondii)
 Pharmacokinetics:  Complete oral absorption and high distribution (less CNS penetration)  70% bound to plasma protein – concentrated in Skin, liver, muscle and kidney  Acetylated and glucoronidae and sulfate conjugated – enterohepatic circulation  Half life 24-36 Hrs, but cumulative (1 – 2 weeks)  ADRs: Generally Well tolerated drug (100 mg /day)  Haemolytic anaemia (oxidizing property) - G-6-PD are more susceptible  Gastric - intolerance, nausea, gastritis  Methaemoglobinaemia, paresthesia, headache, mental symptoms and drug fever  Allergic rashes, FDE, phototoxicity, exfoliative dermatitis and hepatotoxicity etc.
 Sulfone syndrome: Starts after 4- 6 weeks of therapy, more common with MDT  Symptoms: Fever, malaise, lymph node enlargement, desquamation of skin, jaundice and anemia – malnourished patients  Management: stopping of Dapsone in severe cases, corticosteroid therapy  Corticosteroids (prednisolone 40 – 60 mg/day) – severe cases – till reaction controlled – tapered over 8-12 weeks  Dapsone contraindications: Severe anaemia and G-6-PD deficiency and hypersensitivity
 A dye - Leprostatic and anti-inflammatory  MOA: Interferes with template function of DNA in M. leparae  Activity: Used alone resistance (1 -3 years) – but Dapsone resistance cases responds in 2 months (lag period)  Kinetics: orally effective – accumulates in fat in crystalline form – entry to CSF poor – half life 70 days  Used as component of MDT  ADRs: - well tolerated  Reddish-black discolouration of skin – exposed parts  Discolouration of hair and body secretions, dryness of skin and itching, acneform eruptions and phototoxicity – conjunctival pigmentation  GI symptoms: Enteritis with intermittent loose stool, abdominal pain, anorexia and weight loss – early and late symptoms  Should be avoided in pregnancy and liver & kidney disease
 Rifampicin: Cidal. 99.99% killed in 3-7 days, skin symptoms regress within 2 months  Not satisfactory if used alone – persisters even prolonged treatment  Included in MDT to shorten the duration of treatment and also to prevent resistance  Not toxic and no induction of hepatic enzyme - dose as single dose only  Should not be used in ENL and Reversal phenomenon  Ofloxacin: all fluoroquinolones except ciprofloxacin are active. Used as alternative to Rifampicin – 22 daily doses  Minocycline: Lipophillic - enters M leprae. Less marked effect than Rifampicin
 Granulomatous infection – skin,, mucous membrane and nerves  Systems of Classification:  1st (Based on immune system of the patient): Mainly two types: lepromatous (sore on skin, nerves, and other organs) and tuberculoid (sore on skin)  2nd (Ridley-Jopling system – based on symptoms): Borderline tuberculoid leprosy (BL), Borderline lepromatous (BL), Borderline leprosy (BB) and Intermediate leprosy (I)  For operational purposes: WHO  Paucibacillary (>5 lesions): few bacilli and noninfectious – TT and BT and I  Multibacillary (<5 lesions): large bacilli load and infectious – LL, BL and BB types  Single lesion Paucibacillary: single lesion
Paucibacillary (PB) - TT and BT and I Multibacillary (MB) - LL, BL and BB • 1- 5 skin lesions • No nerve/only one nerve involvement +/- 1-5 skin lesions • Skin smear negative at all sites • 6 or more skin lesions • More than one nerve involved irrespective of skin lesions • Skin smear positive at any one of the sites
 Initially (1982) – PBL Dapsone + Rifampicin for 6 Months and MBL – Dapsone + Rifampicin + Clofazimine – 2 years or till disease inactivity/smear negative – with added 5 years surveillance for MBL cases  However, 12 years study (in 1994) – fixed duration for 6 months and 2 years was recommended – 12 million to 2.7 million and no resistance  In 1999 – 6 months and 1 year recommended
Drug Paucibacillary (PB) Multibacillary (MB) Rifampicin 600 mg once a month Supervised 600 mg once a month Supervised Dapsone 100 mg daily self administered 100 mg daily self administered Clofazimine - 300 mg once a month Supervised 50 mg daily self administered Duration 6 Months 12 Months
Photo Courtesy: Dr. Anju R. Marak, SM&HO cum DLO and DMO-MCH, Ri-Bhoi District, Meghalaya
1. Lepra Reaction Occurs in LL type (Type – III HSR) – coincides with institution of chemotherapy or intercurrent infection  Arthus type of reaction – release of antigens from killed bacilli - may be mild, moderate and severe (ENL)  Symptoms: enlarged lesions, become red (inflamed nodules and papules) and painful, new lesions – fever and other constitutional symptoms  Treatment:  Mild analgesics  Mild: Clofazimine - 200 mg daily  Moderate to severe-Steroids: 60 mg/day-Prednisolone - taper off in 2-3 months 2. Reversal reaction Occurs in TT and BL cases (Type II HSR) – delayed hypersensitivity to M. leprae antigens • Symptoms: Cutaneous ulceration, multiple nerve involvement with swollen and tender nerves – occurs suddenly even after completion of therapy …… Treatment: same as above
New Case detection Report
Antileprotic drugs - drdhriti
“The biggest disease today is not leprosy or tuberculosis, but rather the feeling of being unwanted, uncared for, and deserted by everybody.” – Mother Teresa Thank you

More Related Content

Antileprotic drugs - drdhriti

  • 1. Dr. D. K. Brahma Associate Professor Department of Pharmacology NEIGRIHMS, Shillong
  • 2.  Leprosy is caused by a slow-growing type of bacteria called Mycobacterium leprae (M. leprae)  Also known as Hansen's disease, after the scientist who discovered M. leprae in 1873 - Dr. Gerhard Henrik Armauer Hansen of Norway  Bears social stigma  It primarily affects the skin, mucous membrane and the peripheral nerves  Long Incubation period (3 – 5 years)  Curable now – deformities/defects – may not reverse
  • 3.  Chaulmoogra oil  Discovery of sulfonamides  1940 onwards 1. Sulfones – Dapsone ( DDS) 2. Phenazine derivative - Clofazimine 3. Antitubercular drugs - Rifampicin, Ethionamide 4. Other Antibiotics: Ofloxacin, Moxifloxacin, Minocycline and Clarithromycin
  • 4.  The simplest, oldest, cheapest, most active and most commonly used  Diamino diphenyl sulfone (DDS)  MOA:  Leprostatic even at low concentration – higher conc. Arrests growth of may other bacteria  Chemically related to Sulfonamides – same mechanism – inhibition of incorporation of PABA into folic acid (folic acid synthase)  Specificity to M leprae – affinity for folate synthase  Doses for acute infection – too toxic  Activity:  Used alone – resistance – MDT needed  Resistance – Primary and Secondary (mutation of folate synthase – lower affinity)  2.5% to 40% Vs 20% Resistance  However, 100 mg/day – high MIC -500 times and continued to be effective to low and moderately resistant Bacilli (low % of resistant patient)  Persisters. Also has antiprotozoal action (Falciparum and T. gondii)
  • 5.  Pharmacokinetics:  Complete oral absorption and high distribution (less CNS penetration)  70% bound to plasma protein – concentrated in Skin, liver, muscle and kidney  Acetylated and glucoronidae and sulfate conjugated – enterohepatic circulation  Half life 24-36 Hrs, but cumulative (1 – 2 weeks)  ADRs: Generally Well tolerated drug (100 mg /day)  Haemolytic anaemia (oxidizing property) - G-6-PD are more susceptible  Gastric - intolerance, nausea, gastritis  Methaemoglobinaemia, paresthesia, headache, mental symptoms and drug fever  Allergic rashes, FDE, phototoxicity, exfoliative dermatitis and hepatotoxicity etc.
  • 6.  Sulfone syndrome: Starts after 4- 6 weeks of therapy, more common with MDT  Symptoms: Fever, malaise, lymph node enlargement, desquamation of skin, jaundice and anemia – malnourished patients  Management: stopping of Dapsone in severe cases, corticosteroid therapy  Corticosteroids (prednisolone 40 – 60 mg/day) – severe cases – till reaction controlled – tapered over 8-12 weeks  Dapsone contraindications: Severe anaemia and G-6-PD deficiency and hypersensitivity
  • 7.  A dye - Leprostatic and anti-inflammatory  MOA: Interferes with template function of DNA in M. leparae  Activity: Used alone resistance (1 -3 years) – but Dapsone resistance cases responds in 2 months (lag period)  Kinetics: orally effective – accumulates in fat in crystalline form – entry to CSF poor – half life 70 days  Used as component of MDT  ADRs: - well tolerated  Reddish-black discolouration of skin – exposed parts  Discolouration of hair and body secretions, dryness of skin and itching, acneform eruptions and phototoxicity – conjunctival pigmentation  GI symptoms: Enteritis with intermittent loose stool, abdominal pain, anorexia and weight loss – early and late symptoms  Should be avoided in pregnancy and liver & kidney disease
  • 8.  Rifampicin: Cidal. 99.99% killed in 3-7 days, skin symptoms regress within 2 months  Not satisfactory if used alone – persisters even prolonged treatment  Included in MDT to shorten the duration of treatment and also to prevent resistance  Not toxic and no induction of hepatic enzyme - dose as single dose only  Should not be used in ENL and Reversal phenomenon  Ofloxacin: all fluoroquinolones except ciprofloxacin are active. Used as alternative to Rifampicin – 22 daily doses  Minocycline: Lipophillic - enters M leprae. Less marked effect than Rifampicin
  • 9.  Granulomatous infection – skin,, mucous membrane and nerves  Systems of Classification:  1st (Based on immune system of the patient): Mainly two types: lepromatous (sore on skin, nerves, and other organs) and tuberculoid (sore on skin)  2nd (Ridley-Jopling system – based on symptoms): Borderline tuberculoid leprosy (BL), Borderline lepromatous (BL), Borderline leprosy (BB) and Intermediate leprosy (I)  For operational purposes: WHO  Paucibacillary (>5 lesions): few bacilli and noninfectious – TT and BT and I  Multibacillary (<5 lesions): large bacilli load and infectious – LL, BL and BB types  Single lesion Paucibacillary: single lesion
  • 10. Paucibacillary (PB) - TT and BT and I Multibacillary (MB) - LL, BL and BB • 1- 5 skin lesions • No nerve/only one nerve involvement +/- 1-5 skin lesions • Skin smear negative at all sites • 6 or more skin lesions • More than one nerve involved irrespective of skin lesions • Skin smear positive at any one of the sites
  • 11.  Initially (1982) – PBL Dapsone + Rifampicin for 6 Months and MBL – Dapsone + Rifampicin + Clofazimine – 2 years or till disease inactivity/smear negative – with added 5 years surveillance for MBL cases  However, 12 years study (in 1994) – fixed duration for 6 months and 2 years was recommended – 12 million to 2.7 million and no resistance  In 1999 – 6 months and 1 year recommended
  • 12. Drug Paucibacillary (PB) Multibacillary (MB) Rifampicin 600 mg once a month Supervised 600 mg once a month Supervised Dapsone 100 mg daily self administered 100 mg daily self administered Clofazimine - 300 mg once a month Supervised 50 mg daily self administered Duration 6 Months 12 Months
  • 13. Photo Courtesy: Dr. Anju R. Marak, SM&HO cum DLO and DMO-MCH, Ri-Bhoi District, Meghalaya
  • 14. 1. Lepra Reaction Occurs in LL type (Type – III HSR) – coincides with institution of chemotherapy or intercurrent infection  Arthus type of reaction – release of antigens from killed bacilli - may be mild, moderate and severe (ENL)  Symptoms: enlarged lesions, become red (inflamed nodules and papules) and painful, new lesions – fever and other constitutional symptoms  Treatment:  Mild analgesics  Mild: Clofazimine - 200 mg daily  Moderate to severe-Steroids: 60 mg/day-Prednisolone - taper off in 2-3 months 2. Reversal reaction Occurs in TT and BL cases (Type II HSR) – delayed hypersensitivity to M. leprae antigens • Symptoms: Cutaneous ulceration, multiple nerve involvement with swollen and tender nerves – occurs suddenly even after completion of therapy …… Treatment: same as above
  • 17. “The biggest disease today is not leprosy or tuberculosis, but rather the feeling of being unwanted, uncared for, and deserted by everybody.” – Mother Teresa Thank you